REFERENCES
- Morton LM, Wang S, Devesa S, Hartge P, Weisenburger D, Linet M. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 2006; 107: 265–276.
- Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 1993; 20(5 Suppl 5): 75-88.
- Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W for the German Low Grade Lymphoma Study Group (GLSG). The Follicular Lymphoma International Prog-nostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophos-phamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108 (5): 1504–1508.
- Tilly H, Zelenetz A. Treatment of follicular lymphoma: current status. Leuk Lymphoma. 2008;49 Suppl 1: 7–17.
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.Blood,2005; 105 (4): p. 1417–23.
- Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24(4 Suppl 10): p. 510-3-S10-10.
- Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma is dose intensity an emerging para-digm for better outcomes? Ann Oncol, 2005; 16 (9): 1413–24.
- Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, et al. Dose-intense chemother-apy every 2 weeks with dose-intense cyclophosphamide, dox-orubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol, 2003; 21 (13): 2466–73.
- http://ctep.cancengov/protocolDevelopment/elec-tronic applications/ctc.htn
- Garcia-Conde J, Conde E, Sierra J, Caballero D, Arranz R, Leon A, et al. Rituximab (IDEC-C2B8) and CVP chemother-apy in follicular of low grade b-cell lymphoma after relapse: results after 6 months of follow-up. Proc Am Soc Clin Oncol, 2000. 19: p. (abstr 96).
- Klasa RJ, Meyer RM, Shustik C, Sawka CA, Smith A, Guevin R, et al. Randomized phase III study of fludarabine phos-phate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol, 2002; 20 (24): 4649–54.
- Herold M, Schuize A, Niederwieser D, Franke A, Fricke HJ, Richter P, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and man-tle cell lymphoma: results of a randomized phase III trial (OSHO# 19). J Cancer Res Clin Oncol, 2006;132 (2): 105–12.
- Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of flu-darabine phosphate compared with cyclophosphamide, vin-cristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol, 2006; 24 (10): 1590–6.
- Hochster HS, Weller E, Gascoyne RD, Ryan T, Haber-mann TM, Gordon LI, et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB Intergroup E1496 trial. Journal of Clinical On-cology, 2007 ASCO Annual Meeting Proc Part I, 2007; 25(18S): 8004.
- Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D. Dose-related vincristine-induced pe-ripheral neuropathy with unexpected off-therapy worsening. Neurology, 2005; 64 (6): 1076–7.
- Hainsworth JD, Verstappen CP, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol, 2005; 23 (7): 1500–6.
- van Oers MH. Rituximab maintenance therapy: a step for-ward in follicular lymphoma. Haematologica, 2007; 92 (6): 826–33.
- van Oers MH, van Oers HJ, Klasa R, Marcus R, Wolf M, Kimby E, et al. Rituximab maintenance improves clinical out-come of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 2006; 108 (10): 3295–301.